News

November 6, 2018

Adcetris as Stem Cell Transplant Consolidation Therapy Delays Hodgkin’s Progression in Long-term, Data Show

News

Patients with classical Hodgkin’s lymphoma who are at high risk of progressing after a stem cell transplant may benefit significantly from Adcetris (brentuximab vedotin) consolidation treatment in the long-term, researchers found. ... Read more

November 5, 2018

Imbruvica Combo Improves Long-term Survival in CLL/SLL Patients, Updated Phase 3 Results Show

News

Combining AbbVie’s Imbruvica (ibrutinib) with Treanda (bendamustine) and Rituxan (rituximab) improves long-term survival outcomes in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer reappeared or ... Read more

November 5, 2018

MK-1454/Keytruda Combination Shows Promise in Solid Tumor and Lymphoma Patients

News

A combination of the investigational agent MK-1454 and Keytruda (pembrolizumab) induced robust and durable responses in solid tumor and lymphoma patients in a Phase 1 trial, Merck (known as MSD outside the ... Read more

October 31, 2018

BeiGene Asking That Zanubrutinib Be Approved to Treat Advanced CLL/SLL Patients in China

News

Chinese regulatory authorities agreed to review a request that BeiGene’s Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib be approved to treat patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) ... Read more

October 30, 2018

BTK Inhibitor M7583 Shows Significant Benefit in B-Cell Lymphomas in Phase 1 Trial

News

Bruton’s tyrosine kinase (BTK) inhibitor M7583 is proving to be safe and beneficial in patients with refractory or resistant B-cell lymphomas, according to an ongoing Phase 1 trial. Updated trial data ... Read more

October 29, 2018

Targeting B-cell Lymphoma with Natural Killer T-cells May Be More Effective, Cheaper, Preclinical Study Shows

News

Targeting B-cell lymphoma using genetically modified natural killer T-cells — rather than general T-cells — may be a more effective, cheaper, “off-the-shelf” immunotherapy, a preclinical study suggests. The study, “Enhanced ... Read more

October 26, 2018

Orgenesis, Hemogenyx Collaborating on Cell Replacement Technology for Blood Cancers

News

Orgenesis has partnered with Hemogenyx Pharmaceuticals to drive the development and commercialization of Hemogenyx’s human postnatal hemogenic endothelial cell (Hu-PHEC) technology for the treatment of blood cancers. Hu-PHEC is a cell replacement technology designed ... Read more

October 26, 2018October 26, 2018

Zanubrutinib Seen to Halt Tumor Progression in 89% of Waldenström’s Macroglobulinemia Patients in Phase 1 Trial

News

Data from an ongoing Phase 1 trial show that BeiGene’s investigational therapy zanubrutinib is highly active in patients with Waldenström’s macroglobulinemia, a rare type of non-Hodgkin lymphoma. In the trial, 92% ... Read more

October 24, 2018

Leukemia and Lymphoma Society Grants $5M for Development of Blood Cancer Immunotherapies

News

A team of Texas researchers received a grant of $5 million from the Leukemia and Lymphoma Society to develop targeted immunotherapies for blood cancers. The Specialized Center of Research (SCOR) grant will provide ... Read more

October 23, 2018

FDA Grants Priority Review to Imbruvica-Gazyva Combo for First-line Treatment of CLL/SLL

News

The U.S. Food and Drug Administration has granted priority review to AbbVie‘s application seeking the approval of Imbruvica (ibrutinib) plus Gazyva (obinutuzumab) for patients with chronic lymphocytic leukemia or small lymphocytic ... Read more